Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program.
Goldberg R, Temprosa M, Otvos J, Brunzell J, Marcovina S, Mather K, Arakaki R, Watson K, Horton E, Barrett-Connor E. Goldberg R, et al. Among authors: arakaki r. J Clin Endocrinol Metab. 2013 Oct;98(10):3989-98. doi: 10.1210/jc.2013-1452. Epub 2013 Aug 26. J Clin Endocrinol Metab. 2013. PMID: 23979954 Free PMC article. Clinical Trial.
Effects of genetic variants previously associated with fasting glucose and insulin in the Diabetes Prevention Program.
Florez JC, Jablonski KA, McAteer JB, Franks PW, Mason CC, Mather K, Horton E, Goldberg R, Dabelea D, Kahn SE, Arakaki RF, Shuldiner AR, Knowler WC; Diabetes Prevention Program Research Group. Florez JC, et al. Among authors: arakaki rf. PLoS One. 2012;7(9):e44424. doi: 10.1371/journal.pone.0044424. Epub 2012 Sep 11. PLoS One. 2012. PMID: 22984506 Free PMC article. Clinical Trial.
Menopause and risk of diabetes in the Diabetes Prevention Program.
Kim C, Edelstein SL, Crandall JP, Dabelea D, Kitabchi AE, Hamman RF, Montez MG, Perreault L, Foulkes MA, Barrett-Connor E; Diabetes Prevention Program Research Group. Kim C, et al. Menopause. 2011 Aug;18(8):857-68. doi: 10.1097/gme.0b013e31820f62d0. Menopause. 2011. PMID: 21709591 Free PMC article. Clinical Trial.
Diabetes autoantibodies do not predict progression to diabetes in adults: the Diabetes Prevention Program.
Dabelea D, Ma Y, Knowler WC, Marcovina S, Saudek CD, Arakaki R, White NH, Kahn SE, Orchard TJ, Goldberg R, Palmer J, Hamman RF; Diabetes Prevention Program Research Group. Dabelea D, et al. Among authors: arakaki r. Diabet Med. 2014 Sep;31(9):1064-8. doi: 10.1111/dme.12437. Epub 2014 Apr 9. Diabet Med. 2014. PMID: 24646311 Free PMC article. Clinical Trial.
Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes.
Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B; LEAD-3 (Mono) Study Group. Garber A, et al. Diabetes Obes Metab. 2011 Apr;13(4):348-56. doi: 10.1111/j.1463-1326.2010.01356.x. Diabetes Obes Metab. 2011. PMID: 21205128 Free PMC article. Clinical Trial.
Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.
Bode BW, Testa MA, Magwire M, Hale PM, Hammer M, Blonde L, Garber A; LEAD-3 Study Group. Bode BW, et al. Diabetes Obes Metab. 2010 Jul;12(7):604-12. doi: 10.1111/j.1463-1326.2010.01196.x. Diabetes Obes Metab. 2010. PMID: 20590735 Free PMC article. Clinical Trial.
256 results